BioAtla logo

BioAtlaNASDAQ: BCAB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 December 2020

Next earnings report:

26 March 2025

Last dividends:

N/A

Next dividends:

N/A
$74.69 M
-92%vs. 3y high
40%vs. sector
-vs. 3y high
-vs. sector
-35%vs. 3y high
71%vs. sector
-35%vs. 3y high
69%vs. sector

Price

after hours | Wed, 20 Nov 2024 00:19:25 GMT
$1.54$0.00(0.00%)

Dividend

No data over the past 3 years
$11.00 M-$10.59 M

Analysts recommendations

Institutional Ownership

BCAB Latest News

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript
seekingalpha.com09 November 2024 Sentiment: NEUTRAL

BioAtla, Inc. (NASDAQ:BCAB ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Jeet Mukherjee - BTIG Tony Butler - Rodman & Renshaw Yu He - H.C. Wainwright Operator Good day, everyone, and welcome to today's BioAtla Third Quarter 2024 Earnings Call.

BioAtla: Numerous Catalysts Coming In Q4
seekingalpha.com07 October 2024 Sentiment: POSITIVE

BioAtla, Inc. has promising pipeline projects, including masked antibodies and ADCs targeting AXL and ROR2, showing early efficacy and potential for improved cancer treatments. Financially, BioAtla faces challenges with less than a year of cash, despite a licensing deal with Context Therapeutics providing some runway extension. The company's cash position poses a significant risk, necessitating future fundraising, and potentially leading to substantial dilution and market volatility.

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
globenewswire.com04 October 2024 Sentiment: POSITIVE

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.

Michael Burry buys 634,000 shares of this $1 penny stock
finbold.com01 October 2024 Sentiment: POSITIVE

When Michael Burry, the man who famously bet against the housing market before the 2008 financial crash, makes a move, investors take notice.

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
globenewswire.com01 October 2024 Sentiment: POSITIVE

SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced acceptance of an abstract for oral presentation at the upcoming Society for Melanoma Research 21st International Congress (SMR), being held from October 10–13, 2024, in New Orleans, LA.

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
globenewswire.com23 September 2024 Sentiment: POSITIVE

Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated IND filing for BA3362 in mid-2026 SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (“BioAtla”) (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (“CAB”) antibody therapeutics for the treatment of solid tumors, and Context Therapeutics Inc. (“Context”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the companies have entered into an agreement under which Context has obtained from BioAtla an exclusive, worldwide license to develop, manufacture and commercialize BA3362, BioAtla's Nectin-4 x CD3 TCE.

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript
seekingalpha.com11 August 2024 Sentiment: NEUTRAL

BioAtla, Inc. (NASDAQ:BCAB ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Jay Short - Chairman, Co-Founder and CEO Richard Waldron - Chief Financial Officer Dr. Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Brian Cheng - JPMorgan Arthur He - H.C. Wainwright Operator Good day, everyone.

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
globenewswire.com25 July 2024 Sentiment: POSITIVE

SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today hosted a virtual R&D Day on its novel conditionally and reversibly active antibody drug conjugate mecbotamab vedotin, targeting the receptor tyrosine kinase AXL, and its antibody targeting CTLA-4, evalstotug. The R&D Day also featured renowned key opinion leaders, Dr. Edwin Yau, Dr. Omid Hamid and Dr. Ankit Mangla.

BioAtla to Participate in the Jefferies Global Healthcare Conference
globenewswire.com29 May 2024 Sentiment: POSITIVE

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in a fireside chat and one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in New York, NY June 4–6, 2024.

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
globenewswire.com23 May 2024 Sentiment: POSITIVE

Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug

What type of business is BioAtla?

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

What sector is BioAtla in?

BioAtla is in the Healthcare sector

What industry is BioAtla in?

BioAtla is in the Biotechnology industry

What country is BioAtla from?

BioAtla is headquartered in United States

When did BioAtla go public?

BioAtla initial public offering (IPO) was on 16 December 2020

What is BioAtla website?

https://www.bioatla.com

Is BioAtla in the S&P 500?

No, BioAtla is not included in the S&P 500 index

Is BioAtla in the NASDAQ 100?

No, BioAtla is not included in the NASDAQ 100 index

Is BioAtla in the Dow Jones?

No, BioAtla is not included in the Dow Jones index

When was BioAtla the previous earnings report?

No data

When does BioAtla earnings report?

The next expected earnings date for BioAtla is 26 March 2025